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oral phosphate binder Lenziaren® in healthy cats
fed a standard diet
Jonathan N King1*, Heidi L Erasmus2, Peet C Delport2, Ina CJ Bester2 and Wolfgang Seewald1Abstract
Background: The efficacy, acceptability and tolerability of the new oral phosphate binder Lenziaren® (SBR759) were
evaluated in a randomized parallel-group design study in 36 healthy cats (n = 6 per group). Five groups were fed
once daily with a commercial diet containing 0.2% phosphorus (“standard diet”) into which was mixed Lenziaren®
at 0.25, 0.5, 1.0 or 2.0 g/day or no treatment (control group) daily for 30 days. A sixth group was fed a commercial
diet containing lower amounts (0.12%) of phosphorus (“renal diet”) and no treatment.
Results: When compared to the control group, Lenziaren® produced significant dose-related reductions in urine
phosphate concentrations, urine phosphate excretion and fractional urinary phosphate excretion. Significant effects
versus the control group were observed at the 0.5, 1.0 and 2.0 g/day dosages. Lenziaren® was well tolerated and
was associated with higher food consumption and serum iron concentrations versus the control.
When compared to the control group, the renal diet was associated with significantly lower urine phosphate
concentrations and loss of body weight. Lenziaren® had similar effects on urine phosphate concentrations
compared to the renal diet, but was not associated with loss of body weight.
Conclusions: Lenziaren® was effective as an oral phosphate binder in cats fed with a standard diet containing 0.2%
phosphorus. The acceptability and tolerability were good. Dosages of 0.5-1.0 g/cat per day are recommended for
clinical testing in cats fed with a standard diet.
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Disorders of calcium and phosphate metabolism are a
frequent consequence of chronic kidney disease (CKD)
in cats. In cases of CKD, reduction in the excretory func-
tion of the kidney can lead to an increase in plasma
phosphate concentrations unless oral intake of phos-
phate is reduced [1]. Elevated plasma phosphate concen-
trations correlate with a poor prognosis in cats with
CKD [2-5] and therefore treatment guidelines for CKD
in cats recommend monitoring of plasma phosphate
concentrations and, where appropriate, restriction of
oral phosphate intake [6].
Restriction of oral intake of phosphate in cats is achieved
most commonly via the feeding of diets containing low* Correspondence: jonathan.king@novartis.com
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unless otherwise stated.amounts of phosphorus (hereafter referred to as “renal
diet”). Benefits of renal diets in cats have been reported in
experimental models [7], prospective field studies [2,8] and
a retrospective field study [9]. However renal diets may not
be effective alone in maintaining plasma phosphate con-
centrations in the recommended target ranges [6] and
many renal diets have relatively low palatability in cats
[2,10]. Phosphate binders, which reduce the oral absorp-
tion of dietary phosphate, are therefore useful agents in the
management of hyperphosphataemia [11].
A number of phosphate binders are used in cats
including Ipakitine® (calcium carbonate), Lantharenol® or
Renalzin® (lanthanum carbonate octahydrate) and vari-
ous products registered for use in humans containing
aluminium or calcium [11,12]. However, none of the
available phosphate binders are ideal for use in cats due
to low palatability and/or safety issues related to the oral
absorption of aluminium, calcium or lanthanum.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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which consists of an insoluble complex of iron (III) oxide/
hydroxide with starch and sucrose. Lenziaren® does not
contain aluminium, calcium or lanthanum, and there-
fore may have safety advantages over phosphate binders
containing those cations. The efficacy of SBR759 in re-
ducing serum phosphate concentrations has been dem-
onstrated in humans undergoing haemodialysis [13,14].
In healthy cats fed with a renal diet, Lenziaren® was
effective in reducing plasma and urine phosphate
concentrations over the dose range 0.25-1.0 g/cat per
day and had good acceptability and tolerability [15].
The efficacy and tolerability of Lenziaren® in cats with
CKD and hyperphosphataemia and safety in healthy cats
have been reported as abstracts [16,17].
Since not all cats will eat sufficient quantities of renal
diets, it is important to determine the efficacy of phos-
phate binders in cats fed with a “standard” diet. Higher
doses of phosphate binders are anticipated to be needed
with standard diets due to their higher content of phos-
phorus compared to renal diets.
The objective of this study was therefore to evaluate
the efficacy, dose-effect relation, acceptability and toler-
ability of Lenziaren® in healthy cats fed a commercial
standard diet containing 0.2% phosphorus. The study
was a prospective, randomized, masked, parallel-group
comparison of six groups. Five groups received four
different dosages of Lenziaren® or no treatment (control)
plus standard diet. The sixth group was fed with a
prescription renal diet containing 0.12% phosphorus.
Methods
Study animals and approvals
A total of 36 healthy domestic cross-bred cats (18 female
and 18 male) were used. Since one group of cats was
fed a renal diet with restricted phosphate for a total of
up to 9 weeks, and phosphate is necessary for growth
of young animals, the minimum age at study start was
12 months. Each cat was identified via a unique sub-
cutaneous transponder.
The study was conducted at Clinvet International Ltd
(Bloemfontein, Republic of South Africa) in compliance
with the OECD principles of Good Laboratory Prac-
tice, and after approval from the Clinvet Animal Ethics
Committee and Novartis Animal Heath Animal Welfare
Committee. The study was conducted with reference to
the following additional guidelines: VICH guideline GL
43 on target animal safety for pharmaceuticals (EMEA/
CVMP/VICH/393388/2006) and The South African
National Standard SANS 10386:2008 “The care and use
of animals for scientific purposes.” There were no suit-
able non-animal models and therefore in vivo studies
were required to quantify the effect of Lenziaren® on
phosphate balance in cats. The study did not inducepain or distress in the cats, which were purpose-bred
for laboratory studies. Since faeces and urine had to
be collected individually from each animal, the cats
were housed for the duration of the 9 week study indi-
vidually in stainless steel cages in an indoor animal unit.
Each cage was fitted with a rest bench and scratch block,
and cats were interacted with socially at least once per
day. The temperature was 20 (±4) °C with a 12:12 hour
light:dark cycle.
Study schedule
The study schedule is shown in Table 1. The cats were
acclimatized to the cages and introduced to their diets
from day −30. Allocation to the groups (3 females and
3 males per group) was according to randomization
through minimization with body weight as the only
criterion.
General health observations were performed daily, and
detailed clinical examinations were made on days −20, −1,
7, 13, 20 and 27. Lenziaren® may cause darkening of the
faeces due to its iron content, with no known adverse
consequences. Occurrences of darkening of the faeces,
without other detected adverse effects, were therefore re-
corded but were not defined as adverse events. Body
weight was recorded on study days −30, −20, 7, 14, 21
and 28. Food was removed approximately 8–10 hours
before weighing.
Test item
The cats received either 0.25, 0.5, 1.0 or 2.0 g/day
Lenziaren® (Novartis Animal Health Inc, Basel, Switzerland)
or no treatment. The Lenziaren® was weighed and sealed in
plastic sachets for each cat before the day of administration,
and was then mixed on days 0 to 29 with the entire daily
food ration which was offered once per day in the morning.
Lenziaren® is a powder and was sprinkled onto the food
which was stirred gently for at least 30 seconds to allow the
powder to stick to food in a homogeneous manner.
No placebo was used in this study. Since the iron con-
tent of Lenziaren® adds colour and is responsible for its
efficacy, no suitable placebo was available. Since diets in
groups A-E were different versus group F, assessments
of the important endpoints of the study were kept
masked by use of different personnel. Persons not other-
wise involved in the study prepared the diet and test
items in sachets and assigned codes (A-F) to the study
groups, and were not blinded. The people who adminis-
tered the test items to the cats, and assessed the feed
consumption and acceptability of the test items, could
only identify the groups by their codes. The investigators
responsible for clinical examinations were fully blinded
since they had no access to the study codes and were
kept out of sight of the food. At no stage in the study
was it necessary to reveal the blinding code to blinded
Table 1 Study schedule
Study day Action
−30 Body weight and blood collection for
serum phosphate
Ranking and allocation to groups
Start of acclimatization to housing
and diets
Start of daily general health observations
−20 Body weight
Clinical examination
−16 to −12, −9 to −6 and −1 Acceptability test
−14 Blood collection for chemistry and
haematology
72 hour urine collection (baseline)
(−14 to −12)
72 hour faeces collection (baseline)
(−14 to −12)
−1 Clinical examination
0 Start daily administration of Lenziaren®
to groups A-D (day 0 to +29)
Specific health observations (including
hourly for 4 hours post administration
of test item)
0 to +2, +5 to +8, +12 to +14 Acceptability test
+6 72 hour urine collection (+6 to +9)





72 hour urine collection (+13 to +16)




72 hour urine collection (+20 to +23)




72 hour urine collection (+27 to +30)
72 hour faeces collection (+27 to +30)
+28 Body weight
Blood specimen collection
+29 Final administration of Lenziaren®
+30 End of biological phase of study
Deviations of ±2 days were permitted for some activities for logistical reasons.
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data base had been locked.
Diets
The cats were fed one of two wet diets. The standard diet
consisted of Hill's Science Plan Adult 1-6 Optimal Care
Chicken (Hill's Pet Nutrition Inc, Topeka, KS, USA). Infor-
mation from the manufacturer lists that the diet contains
10.4% crude protein, 6.7% crude oils and fats, 0.20%
calcium and 0.18% phosphorus.
The renal diet consisted of Hill’s Prescription® Diet k/d®
Feline Renal Health with Chicken (14%). Information from the
manufacturer lists that the diet contains 7.6% crude protein,
7.0% crude oils and fats, 0.17% calcium and 0.1% phosphorus.
Samples of each batch of food were analyzed to con-
firm the phosphorus content; mean (range) values were
0.2 (0.18-0.22)% for the standard diet (n = 32 batches)
and 0.12 (0.09-0.14)% for the renal diet (n = 9 batches).
The cats were acclimatized to their cages and intro-
duced to their diets (standard diet in groups A-E, renal
diet in group F) from day −30. The daily intake of each
cat was recorded during the last week of acclimatization
and this amount of food was then offered to each cat
daily on days 0 to 29.
Water (ad libitum) and feed were offered in separate
stainless steel bowls.
Assessments
On each day from 0 to 29, the amount of food offered
and not eaten was weighed and the percentage of food
consumed calculated as follows:
Percentage of food consumed %ð Þ ¼ Amount of food consumed
Amount of food offered
 100
The dose of the test item consumed was calculated by
multiplying the percentage of food consumed (as calcu-
lated above) by the nominal dose administered (Table 2).
Since the test item was mixed homogeneously with the
food, the percentage of test item consumed was consid-
ered equal to the percentage food consumed. Food not
eaten 23 hours after offer was removed and considered as
not eaten. In the event that a cat did not eat all of its med-
icated food, additional unmedicated food was not offered.
The acceptability of the food, with or without the test
items, was assessed from the time for each cat to eat
all the food offered during 10 of the last 16 days of
acclimatization (study days −16 to −1) and during 10 of
the first 15 days of the study (days 0 to 14). The time
during which the food was consumed was recorded, to
the nearest one hour, hourly for the first six hours, and
then at approximately 23 hours. If there was still food
remaining at 23 hours, the time during which the food
was consumed was assumed to be 24 hours.
Table 2 Summary of data - part I

















Day −30 3.617 (0.948) 3.445 (0.630) 3.523 (0.880) 3.342 (0.886) 3.413 (0.667) 3.373 (0.536)
Day −20 3.452 (0.894) 3.293 (0.654 3.405 (0.864 3.308 (0.740) 3.355 (0.700) 3.212 (0.490)
Day 28 3.528 (1.003) 3.448 (0.627) 3.500 (1.020) 3.450 (0.745) 3.445 (0.648) 2.953 (0.376)
CFB Day 28 from Day −30 −0.088 (0.228) 0.003 (0.276) −0.023 (0.225) 0.108 (0.475) 0.032 (0.283) −0.420 (0.172)
Mean Days 7-28 3.532 (1.012) 3.430 (0.608) 3.462 (0.990) 3.436 (0.738) 3.465 (0.626) 2.965 (0.399)
CFB Mean Days 7–28 from Day −30 −0.085 (0.191) −0.015 (0.248) −0.061 (0.186) 0.095 (0.430) 0.051 (0.266) −0.409 (0.157)
Food consumed (g/day)
Day −14 183.6 (53.9) 200.5 (25.3) 171.3 (57.4) 197.7 (45.5) 220.4 (65.0) NA
Day 28 174.8 (47.7) 200.4 (25.2) 190.2 (53.4) 202.2 (42.8) 189.5 (51.8) 163.6 (39.0)
CFB Day 28 from Day −14 −8.8 (12.5) −0.1 (0.2) 18.9 (19.5) 4.5 (21.9) −30.9 (36.9) NA
Mean Days 7-28 172.7 (47.0) 198.2 (21.4) 181.9 (46.9) 205.0 (45.7) 198.1 (49.4) 160.2 (41.6)
CFB Mean Days 7–28 from Day −14 −10.9 (16.6) −2.3 (5.6) 10.6 (17.1) 7.3 (24.2) −22.3 (34.4) NA
Serum phosphate concentration (mmol/L)
Day −30 1.64 (0.22) 1.68 (0.36) 1.56 (0.41) 1.66 (0.28) 1.64 (0.42) 1.76 (0.35)
Day 28 1.81 (0.26) 1.71 (0.23) 1.70 (0.15) 1.78 (0.23) 1.68 (0.40) 1.60 (0.10)
CFB Day 28 from Day −30 0.17 (0.27) 0.03 (0.39) 0.15 (0.33) 0.12 (0.25) 0.04 (0.46) −0.16 (0.27)
Mean Days 7-28 1.71 (0.26) 1.70 (0.15) 1.68 (0.13) 1.77 (0.22) 1.70 (0.36) 1.61 (0.14)
CFB Mean Days 7–28 from Day −30 0.07 (0.29) 0.02 (0.27) 0.12 (0.33) 0.11 (0.21) 0.06 (0.44) −0.15 (0.22)
Urine phosphate concentration (mmol/L)
Day −14 67.5 (12.4) 71.8 (36.4) 77.7 (26.4) 78.8 (26.4) 68.7 (16.6) NA
Day 28 85.2 (22.8) 78.7 (19.8) 70.1 (14.6) 59.4 (16.3) 63.0 (12.5) 61.7 (12.2)
CFB Day 28 from Day −14 17.7 (17.6) 6.9 (25.4) −7.6 (34.6) −19.5 (22.7) −5.7 (15.0) NA
Mean Days 7-28 86.3 (23.9) 82.3 (23.5) 77.4 (14.1) 71.8 (15.4) 59.1 (16.6) 65.8 (17.0)
CFB Mean Days 7–28 from Day −14 18.8 (15.9) 10.5 (18.5) −0.3 (27.1) −7.0 (16.3) −9.6 (20.8) NA
Data are mean (SD), CFB = change from baseline.
NA = not applicable.
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and atipamezole) on days −30, −14, 7, 14, 21 and 28 with-
out coagulant for serum chemistry and into EDTA for
haematology. Food was removed approximately 8–10
hours prior to blood collection and weighing. Serum
chemistry variables included alanine aminotransferase
(ALT), alkaline phosphatase (ALP), total calcium, cre-
atinine, iron, phosphorus (serum inorganic phosphate)
and urea. Haematology variables included red cell count,
haematocrit, haemoglobin, total and differential white
cell count, platelet count, prothrombin time and acti-
vated partial thromboplastin time.
Specimens of faeces and urine were collected separ-
ately on days −14 to −12, 6 to 9, 13 to 16, 20 to 23,
and 27 to 30. For each collection session, litter trays
containing Katkor® (Rein Vet Products, The Netherlands
[18]) were placed in the cages during the afternoon andremoved in the morning 3 to 4 days later. This en-
sured the collection of urine (and faeces) during at least
72 hours.
Faeces were collected at least twice a day during each
72 hour collection session. Pieces of Katkor® that had
adhered to faeces were removed. Faeces were then
pooled, frozen and weighed before being freeze dried
and milled to create a fine powder to ensure homogen-
eity. The faecal samples were then analyzed in one run
for phosphorus content using method KJ4 (Association of
Official Analytical Chemists Inc, 1984, Official Methods of
Analysis, 14th Ed).
Urine specimens (≥ 500 μL) were collected at least
twice a day from the trays containing Katkor®. Alter-
native methods (e.g. catheter, cystocentesis or manual
expulsion) were not needed. Because urine concentra-
tion in cats is not constant, a 72 hour pooled specimen
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each 72 hour collection session in each cat was pooled
in two separate containers, weighed and refrigerated.
One container contained 6 N hydrochloric acid to create
a pH of ≤ 3-3.5 in order to stabilize the phosphorus and
the other container contained no additives. The variables
measured were creatinine, phosphate and specific gravity.
Faecal phosphorus excretion was calculated by multi-
plying the weight of the faeces by the concentration of
phosphorus in the faeces.
Urinary phosphate excretion was calculated by multi-
plying the urine volume (mL) by the concentration of
phosphate in the urine. In all samples the urine was
weighed (g) and the volume calculated from the measured
urine specific gravity. The concentration of phosphate in
urine was reported as mmol/L, and was transformed to
concentration of phosphorus (g/L) by multiplying by a fac-
tor of 0.03097.
The total phosphorus excretion was calculated by
adding the urinary phosphorus values to the faecal
phosphorus values.
The phosphorus balance was calculated by:
Phosphorus balance g½  ¼ Phosphorus intake
– Total phosphorus excretion
faeces and urineð Þ
The fractional urinary excretion was calculated by:
Fractional urinary phosphate excretion %½ 
¼ Phosphate in Urine  Creatinine in Serum
Phosphate in Serum  Creatinine in Urine 100
A correction factor of 1/1000 was applied to correct
for differences in units.
Concomitant treatments
Medications known or suspected to be at risk of inter-
acting with the test item or the evaluations used in the
study, or with known adverse effects in cats, were
not permitted during the study. These included anti-
hypertensive agents (including calcium channel blockers
and angiotensin-converting enzyme inhibitors), corticoste-
roids, diuretics, nephrotoxic agents, non-steroidal anti-
inflammatory drugs, other phosphate binding agents or
any product containing phosphates or phosphorus.
Statistics
All analyses and calculations were performed using SAS®
Version 9.2 (SAS Institute Inc, Cary, NC, USA). Unless
stated, data are presented as mean and SD or median
and range. Statistical significance was concluded with
two-sided P values less than 0.05. No correction was
made for multiple analyses (in order not to inflate the
type II error).With the exception of acceptability scores, all efficacy
variables were analyzed using repeated measures ana-
lysis of covariance (RMANCOVA). An auto-regressive
(1) correlation structure between data for the same subject
was assumed. Data were log transformed in some cases to
improve the fit of the model to a normal distribution. In
the primary analysis the effects included in the model
were treatment, day, treatment x day interaction, and with
or without baseline as covariate (see Results section). In a
secondary analysis, percentage of food consumed was
included as an additional covariate. In the event of a sig-
nificant overall treatment effect in the RMANCOVA ana-
lysis, pair-wise group comparisons were obtained from the
RMANCOVA model with no correction for multiple com-
parisons. A trend analysis of dose of SBR759 versus each
variable was included.
We attempted to evaluate the dose–response relation
of Lenziaren® on serum and urine phosphate concentra-
tions using data from groups A-E. However the standard
Hill model (sigmoidal curve) could not be applied as ei-
ther convergence of the model was not achieved or the
slope estimate was not significantly different from zero.
Acceptability was assessed as the time for the cat to
consume their daily ration. Groups were compared using
the Kruskal-Wallis test with post-hoc comparisons using
the Mann–Whitney test.
Clinical chemistry, haematology and urine variables were
evaluated using RMANCOVA (or analysis of covariance
(ANCOVA) if only two time points were available) with
baseline as covariate and day, treatment and treatment x
day interaction as effects.
Results
Cats
The experimental phase of the study was conducted from
March to May 2013. The cats were aged 12–84 months at
study day −30, and weighed 2.42-3.61 kg (females) and
3.03-4.98 kg (males). With the exception of some minor
clinical signs which were judged to be unrelated to the test
item, e.g. conjunctivitis, loose faeces or otitis externa, all
cats remained in good health throughout the study. No
adverse events judged related to Lenziaren® were observed.
As defined in the protocol, darkening of the faeces is an
expected effect of Lenziaren® due its iron content and has
no adverse consequences, and therefore was not reported
as an adverse event.
Test item
The dose of Lenziaren® consumed was estimated from the
percentage amount of food consumed, which for days 1–
28 was 94.5% for the control group E, 99.0%, 94.2%, 98.2%
and 90.6% respectively for Lenziaren® groups A-D, and
96.8% for the renal diet group (F). The estimated daily
doses of Lenziaren® were therefore respectively 0.244,
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0.25, 0.5, 1.0 and 2.0 g/day.
Efficacy endpoints
Summary results for the efficacy endpoints are shown
in Tables 2 and 3. Results of the RMANCOVA ana-
lyses are reported in Tables 4 and 5. In the primary
statistical analysis, the effects tested were treatment, day
and treatment x day interaction, with or without baseline
as covariate. It was planned in the protocol to include
baseline as a covariate for all variables in the analyses.
However, group F (fed with renal diet) lost body weight
during the study, including during the day −30 to day −1
acclimatization period. Baseline values at days −30 and −20
for body weight and day −30 for serum phosphate con-
centration were available for all groups. For all other
variables, the first “baseline” value was obtained on
day −14. Therefore it was decided to perform the fol-
lowing RMANCOVA analyses:
1) Groups A-E (Lenziaren® and negative control) were
compared using the baseline values at day −30 for
body weight and serum phosphate concentration,
and day −14 for all other variables, since groups A-E
were managed the same before day 0.
2) Groups A-F were compared for two variables, body
weight and serum phosphate concentration, using
the available baseline value at day −30, since all
groups were managed the same before day −29.
3) Groups A-F were compared for all variables except
body weight and serum phosphate concentration
without baseline in the model, since the group F
was not managed the same as groups A-E between
days −29 and −1.
In a secondary analysis, percentage of food consumed
was included as an additional covariate and was significant
(P < 0.05) for many variables (serum and urine phosphate
concentrations, phosphorus consumed, phosphorus ex-
creted in faeces and in total, and phosphorus balance).
However there were no relevant differences in results
(including overall treatment effect, dose-trend test or post-
hoc group comparisons) for any variable with and without
percentage food consumed included as a covariate. There-
fore results of the secondary analyses, with food consump-
tion included as a covariate, are not shown in this paper.
In one half of the RMANCOVA analyses model data did
not fit a normal distribution, in spite of the use of a log
transformation in 70% of the analyses (Tables 4 and 5).
Body weight
There were no significant differences in body weights
between groups A-E and no dose trend for Lenziaren®
(Figure 1, Table 4). When group F was included in theanalyses (Table 5), there was a significant treatment
(P = 0.0296) effect and in the post-hoc analyses the body
weight in group F was significantly lower than groups A-E.
The change from baseline analysis (day −30 to day 30)
showed a mean (%) 0.03 kg (0.9%) weight gain with the
Lenziaren® groups A-D combined, 0.42 kg (12.4%) weight
loss in group F, and a 0.088 kg (2.4%) weight loss in the
control group E (Figure 1, Table 2). Cats in group F lost
most body weight from days −30 to 7 with a lesser decline
from day 7 to day 28 (Figure 1).
Food consumed
For the day 0 to 30 period, the mean food consumption
was respectively 14.7, 5.3, 18.7 and 14.7% higher in the
0.25, 0.5, 1.0 and 2.0 g/day Lenziaren® groups A-D com-
pared to the control group E (Table 2). There was a
significant treatment effect (P = 0.043) with groups B
and C having significantly higher food consumption than
groups D and E (Table 4).
When group F was included in the model, there was no
significant treatment effect (P = 0.39) although the mean
food consumption on days 7–28 in group F (160.2 g/day)
was 7.3% lower than the control group E (172.7 g/day).
Mean food consumption in group F increased progres-
sively during the study: mean daily food consumption in
group F was 150.1, 156.1, 159.6, 161.3 and 163.6 g/day on
days −14, 7, 14, 21 and 28 respectively (Table 5).
Acceptability
The acceptability of the food and Lenziaren® was assessed
from the amount of uneaten food remaining at the end of
every hour for six hours for 10 days before (days −16
to −1) and for 10 days after (days 0 to 14) administering
the test item. There were no significant differences either
for the all-group comparisons using the Kruskal-Wallis test
or for paired comparisons between groups using the
Mann–Whitney test (data not shown). Therefore it was
concluded that Lenziaren® had no significant effect on ac-
ceptability of the standard diet. The number of cats which
did not consume all of their food within 23 hours in groups
A-F was respectively 1, 3, 5, 5, 3 and 4 over the day 6–8
period and 3, 2, 3, 4, 2 and 3 over the day 26 to 28 period.
Serum phosphate concentration
There was no significant treatment effect on serum
phosphate concentrations for the group A-E or A-F ana-
lyses (Tables 4 and 5). However in the group A-E analysis,
there was a significant (P = 0.02) dose trend test with
higher serum phosphate concentrations with increasing
dose of Lenziaren®.
Urine phosphate concentration
In the group A-E analysis, there were highly significant
treatment effect (P = 0.0076) and dose trend (P = 0.0003)
Table 3 Summary of data - part II
















Phosphorus consumed (g/3 days)
Day −14 1.102 (0.323) 1.203 (0.152) 1.028 (0.344) 1.186 (0.273) 1.322 (0.390) NA
Day 28 1.049 (0.286) 1.202 (0.151) 1.141 (0.320) 1.213 (0.257) 1.137 (0.311) 0.567 (0.135)
CFB Day 28 from Day −14 −0.053 (0.075) −0.001 (0.001) 0.113 (0.117) 0.027 (0.132) −0.185 (0.222) NA
Mean Days 7-28 1.036 (0.282) 1.189 (0.128) 1.091 (0.281) 1.230 (0.274) 1.188 (0.296) 0.555 (0.144)
CFB Mean Days 7–28 from Day −14 −0.066 (0.100) −0.014 (0.034) 0.064 (0.103) 0.044 (0.145) −0.134 (0.207) NA
Phosphorus excreted in faeces (g/3 days)
Day −14 0.708 (0.475) 0.778 (0.260) 0.694 (0.415) 0.798 (0.318) 0.735 (0.128) NA
Day 28 0.810 (0.197) 0.960 (0.222) 0.888 (0.447) 0.877 (0.304) 0.730 (0.245) 0.433 (0.085)
CFB Day 28 from Day −14 0.102 (0.390) 0.182 (0.251) 0.194 (0.375) 0.080 (0.114) −0.005 (0.165) NA
Mean Days 7-28 0.716 (0.153) 0.906 (0.205) 0.819 (0.256) 0.901 (0.268) 0.809 (0.287) 0.338 (0.075)
CFB Mean Days 7–28 from Day −14 0.008 (0.360) 0.127 (0.165) 0.125 (0.245) 0.103 (0.131) 0.074 (0.234) NA
Phosphorus excreted in urine (g/3 days)
Day −14 0.257 (0.083) 0.179 (0.134) 0.295 (0.114) 0.159 (0.060) 0.240 (0.149) NA
Day 28 0.390 (0.190) 0.420 (0.120) 0.321 (0.117) 0.320 (0.148) 0.166 (0.118) 0.229 (0.091)
CFB Day 28 from Day −14 0.068 (0.132) 0.163 (0.122) 0.040 (0.055) 0.167 (0.142) −0.020 (0.086) NA
Mean Days 7-28 0.353 (0.111) 0.383 (0.105) 0.320 (0.115) 0.304 (0.109) 0.204 (0.147) 0.189 (0.049))
CFB Mean Days 7–28 from Day −14 0.096 (0.089) 0.204 (0.081) 0.025 (0.058) 0.144 (0.124) −0.037 (0.098) NA
Total phosphorus excreted (g/3 days)
Day −14 0.965 (0.549) 0.958 (0.327) 0.989 (0.522) 0.957 (0.312) 0.976 (0.204) NA
Day 28 1.201 (0.331) 1.380 (0.230) 1.209 (0.490) 1.197 (0.439) 0.896 (0.328) 0.661 (0.166)
CFB Day 28 from Day −14 −0.011 (0.437) 0.179 (0.188) 0.145 (0.301) 0.243 (0.235) 0.123 (0.408) NA
Mean Days 7-28 1.068 (0.247) 1.289 (0.277) 1.139 (0.354) 1.205 (0.372) 1.013 (0.405) 0.526 (0.118)
CFB Mean Days 7–28 from Day −14 0.103 (0.370) 0.331 (0.197) 0.150 (0.245) 0.247 (0.136) 0.037 (0.261) NA
Phosphorus balance (g/3 days)
Day −14 0.137 (0.283) 0.245 (0.296) 0.039 (0.245) 0.229 (0.200) 0.347 (0.254) NA
Day 28 −0.152 (0.208) −0.178 (0.282) −0.068 (0.348) 0.016 (0.327) 0.241 (0.192) −0.094 (0.052)
CFB Day 28 from Day −14 −0.288 (0.300) −0.423 (0.262) −0.106 (0.263) −0.213 (0.240) −0.106 (0.206) NA
Mean Days 7-28 −0.032 (0.197) −0.100 (0.262) −0.048 (0.171) 0.025 (0.220) 0.175 (0.177) 0.029 (0.047)
CFB Mean Days 7–28 from Day −14 −0.169 (0.369) −0.345 (0.187) −0.087 (0.165) −0.204 (0.113) −0.171 (0.341) NA
Fractional urinary phosphate excretion (%)
Day −14 17.96 (4.47) 16.57 (3.36) 20.75 (4.63) 19.64 (5.30) 17.60 (4.71) NA
Day 28 18.60 (7.21) 17.91 (5.70) 18.44 (5.71) 15.17 (2.25) 11.37 (3.71) 16.97 (2.41)
CFB Day 28 from Day −14 0.63 (4.02) 1.34 (4.15) −2.32 (6.01) −4.47 (5.22) −6.23 (1.49) NA
Mean Days 7-28 20.39 (6.68) 19.18 (3.43) 17.90 (4.34) 17.25 (2.23) 12.93 (5.09) 15.27 (3.26)
CFB Mean Days 7–28 from Day −14 2.42 (3.36) 2.61 (2.25) −2.85 (4.43) −2.39 (3.58) −4.67 (2.16) NA
Data are mean (SD), CFB = change from baseline.
NA = not applicable.
King et al. BMC Veterinary Research 2014, 10:258 Page 7 of 13
http://www.biomedcentral.com/1746-6148/10/258tests, with lower urine phosphate concentrations with
increasing dose of Lenziaren® (Table 4). In the post-
hoc analyses, urine phosphate concentrations weresignificantly lower in groups C and D (1.0 and 2.0 g/day
Lenziaren®) compared to the control, and also in D
(2.0 g/day Lenziaren®) versus groups A and B.
Table 4 Summary of RMANCOVA analyses for control and Lenziaren® groups only (groups A-E)
Variable Transformation Normality
P value
P values for model effects in RMANCOVA
Treatment Baseline* Day Treatment x day
interaction
P < 0.05 in post
hoc comparisons
Dose trend**
Body weight Log 0.1698 0.9223 < 0.0001 0.4523 0.2702 None significant 0.31
Food consumed Log < 0.0001 0.0434 < 0.0001 0.9959 0.4724 B & C > D & E 0.91
Serum phosphate
concentration
Log 0.5181 0.1501 < 0.0001 0.4910 0.4898 D > E 0.020 inc
Urine phosphate
concentration
None 0.4201 0.0076 0.0005 0.0428 0.0455 C < E 0.0003 dec
D < A, B & E
Phosphorus consumed None < 0.0001 0.0266 < 0.0001 0.9904 0.4527 B & C > D & E 0.9299
Phosphorus excreted
in faeces
Log 0.6280 0.4867 < 0.0001 < 0.0001 0.6309 None significant 0.4854
Phosphorus excreted
in urine
Log 0.6590 0.0040 0.0001 0.0087 0.1695 B < A 0.0064 dec
D < A, C & E
Total phosphorus excreted Log 0.3264 0.1518 < 0.0001 < 0.0001 0.3878 A < D 0.0938
Phosphorus balance Log 0.0242 0.2554 0.0184 < 0.0001 0.8813 A < D 0.0878
Fractional urinary
phosphate excretion
None 0.6858 0.0001 < 0.0001 0.0222 0.8098 B & C < A & E < 0.0001 dec
D < A, B, C & E
*The baseline used in the model was day −30 for body weight and serum phosphate concentration, and day −14 for all other variables.
**dec = decrease, inc = increase.
Values in bold indicate statistical significance (P < 0.05).
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overall treatment effect (P = 0.0337) with significantly
lower concentrations in groups D (2.0 g/day Lenziaren®)
and F (renal diet) compared to the control (E) group
(Table 5).
Compared to the control group (E), mean urine phos-
phate concentrations at day 30 were respectively 7.6,
17.7, 30.3, 26.1 and 27.6% lower in groups A, B, C, D







Body weight Log 0.0009 0.0296
Food consumed Log 0.0049 0.3882
Serum phosphate concentration Log 0.0266 0.6387
Urine phosphate concentration None 0.5206 0.0337
Phosphorus consumed None 0.0259 < 0.00
Phosphorus excreted in faeces Log 0.9238 0.0004
Phosphorus excreted in urine Log 0.0445 0.0196
Total phosphorus excreted Log 0.3241 0.0021




*The baseline in the model for variables body weight and serum phosphate concentra
Values in bold indicate statistical significance (P < 0.05).Phosphorus consumed
There was a significant treatment effect in both the
group A-E and A-F analyses. In the post-hoc analyses for
the group A-E analysis, the phosphorus consumption was
higher in groups B and C (0.5 and 1.0 g/day Lenziaren®)
compared to groups D and E, reflecting the respective
higher food consumption (Table 4).
In the post-hoc analysis for group A-F, the phosphorus
consumption was significantly lower in group F (renal diet)es for model effects in RMANCOVA
ent Baseline* Day Treatment x day
interaction
P < 0.05 in post hoc
comparisons
< 0.0001 0.8576 0.1674 A, B, C, D & E > F
0.9961 0.7012 None significant
0.0030 0.5919 0.3622 None significant
0.0023 0.0714 D < A, B & E F < E
01 0.9806 0.7083 F < A, B, C, D & E
< 0.0001 0.1576 F < A, B, C, D & E
0.0123 0.1278 D<A & E F <A, B & E
< 0.0001 0.0470 F < A, B, C, D & E
< 0.0001 0.2730 D < A, B & E
0.0241 0.3375 D < A, B, C & E


















B 0.25 g/day Lenziaren
C 0.5 g/day Lenziaren
D 1.0 g/day Lenziaren
E 2.0 g/day Lenziaren
F Renal diet
Figure 1 Mean and SD body weight. Renal diet (group F) or standard diet (groups A-E) were fed from day −30 to 29. Lenziaren® was administered
to groups A, B, C and D on days 0 to 29.
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explained by a combination of lower dietary phosphate
content (0.12% in group F versus 0.2% in groups A-E) plus
the lower food consumption in group F.
Phosphorus excreted in faeces
In the group A-E analysis, there was no significant treat-
ment effect or dose-trend test (Table 4). In the group
A-F analysis, there was a significant treatment effect
with the amount of phosphorus excreted in the faeces
significantly lower in group F (renal diet) compared to
all other groups (A-E) (Table 5). This result correlates
with the lower dietary content of phosphorus and food
consumption in group F.
Phosphorus excreted in urine
In the group A-E analysis, there was a significant treat-
ment effect (P = 0.0040) and dose-trend test (P = 0.0064)
with a lower amount of phosphorus excreted in the
urine with higher dose of Lenziaren® (Table 4). In the
post-hoc tests, the amount excreted was lower in group D
(2.0 g/day Lenziaren®) versus A, C and E, and in group B
(0.5 g/day Lenziaren®) versus A.
In the group A-F analysis, there was a significant treat-
ment effect (P = 0.0196) and in the post-hoc comparisons
group F (renal diet) had lower values than groups A, B
and E (Table 5).
Total phosphorus excreted
In the group A-E analysis, there was no treatment effect
or dose trend test in the total phosphorus excreted
(Table 4).In the group A-F analysis, there was a significant
(P = 0.0021) treatment effect, and in the post-hoc analysis
values were lower with group F (renal diet) versus all other
groups (A-E) (Table 5).
Phosphorus balance
There was no significant treatment effect in both the
group A-E and group A-F analyses (Tables 4 and 5).
Fractional urinary excretion
In the group A-E analysis, there was a highly signifi-
cant treatment effect (P = 0.0001) and dose-trend test
(P < 0.0001) with lower fractional excretion with higher
dose of Lenziaren® (Table 4). In the post-hoc compari-
sons, the excretion was significantly lower in groups B
and C (0.5 and 1.0 g/day Lenziaren®) versus A and E, and
in group D (2.0 g/day Lenziaren®) versus A, B, C and E.
At the day 30 time point, the fractional excretion was
3.7, 0.9, 18.4 and 38.9% lower in groups A, B, C and D
respectively compared to the control group E (Table 3).
In the group A-F analysis, there was a significant treat-
ment effect (P = 0.046) but no significant effect of group F
(renal diet) in the post-hoc analysis (Table 5). The frac-
tional urinary excretion in group F was 8.8% lower than
the control group.
Clinical chemistry, haematology and urine variables
In the comparisons of groups A-E, there were significant
dose trends for ALP (P = 0.012, decrease), ALT (P = 0.023,
decrease), creatinine (P = 0.0070, increase) and iron
(P = 0.0049, increase). In the post-hoc comparisons,
groups C and D (1.0 and 2.0 g/day) were significantly
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Group D was significantly different from E for ALP.
Mean (SD) iron concentrations (μmol/L) from day 0
to 28 were 16.0 (2.9) in group A, 22.0 (6.6) in group B,
21.6 (5.9) in group C, 20.4 (5.2) in group D, 16.2 (7.0) in
group E and 21.0 (4.7) in group F. These values repre-
sent change from baseline of (μmol/L) 2.0 (1.7), 3.2 (3.8),
5.1 (5.1) and 4.6 (6.8) respectively in the Lenziaren®
(A-D), −1.0 (3.3) in the control (E) and −3.8 (5.0) in
the renal diet (F) groups.
Amylase, platelet and potassium values were signifi-
cantly higher in group F (renal diet) compared to group E
(control).
Discussion
The primary objective of this study was to determine
the efficacy and dose-effect relation of the new oral
phosphate binder Lenziaren® in healthy cats fed with a
standard diet (containing ~0.2% phosphorus). This ob-
jective was fulfilled by the comparison of four dosages
of Lenziaren® (0.25-2.0 g/day) to the control group. The
results demonstrate that Lenziaren® effectively bound
phosphate present in the diet, as evidenced by the sig-
nificantly lower urine phosphate concentrations, urine
phosphorus excretion and fractional urinary phosphate
excretion. These effects occurred in spite of higher food
consumption and therefore higher phosphorus intake
with Lenziaren® compared to the control group. The ef-
ficacy of Lenziaren® was dose-dependent over the tested
dosage range of 0.25–2.0 g/day, with significant effects
versus the control at 0.5, 1.0 and 2.0 g/day on fractional
urinary phosphate excretion, 1.0 and 2.0 g/day on urine
phosphate concentration and 2.0 g/day on urine phos-
phorus excretion. The results indicate that a higher dose
of Lenziaren®, approximately two times higher, was re-
quired to reduce urine phosphate concentrations by an
equivalent amount when administered with standard diet
in this study compared to a renal diet in a previous study
[15]. This is an expected result due to the higher content
of phosphorus in the standard diet (0.2%) compared to
the renal diet (0.12%) tested. Therefore we can recom-
mend that Lenziaren® be administered at a starting dose
of 0.25 g/day, with an increase up to 1.0 g/day as needed,
in cats fed with a renal diet. However a starting dose of
0.5 g/day with increase up to 1.0 g/day as needed may be
a better recommendation in cats fed with a standard diet.
These predictions require testing in field studies with cats
with clinical hyperphosphataemia.
The results, showing that Lenziaren® is an effective oral
phosphate binder over the dose range 0.5–2.0 g/day, are
consistent with results from previous studies. In healthy
cats fed with a renal diet, Lenziaren® significantly reduced
serum and urine phosphate concentrations over the dose
range 0.25-1.0 g/day [15]. In cats with hyperphosphataemiaand CKD, Lenziaren® reduced serum phosphate concentra-
tions over the dose range 0.25-1.0 g/day [17]. The efficacy
of SBR759 in human patients with hyperphosphataemia
undergoing dialysis has also been reported over the dose
range 3.75-22.5 g/day [13].
The tolerability of Lenziaren® in this study was good,
as assessed from the lack of reported adverse effects
attributed to the test item. Lenziaren® had no detected
negative impact on acceptability or intake of the food
(standard diet), and in fact food consumption and body-
weight gain were higher with Lenziaren® compared to
the control and renal diet groups.
Significantly higher serum creatinine, iron and phosphate
concentrations and significantly lower ALP and ALT
activities were observed with higher doses of Lenziaren®.
An oral phosphate binder would be expected to decrease
serum phosphate concentrations, however homeostatic
mechanisms in healthy cats could have maintained serum
concentrations during the relatively short duration (30 days)
of administration of Lenaziaren®. It is not clear why the
serum phosphate concentrations showed a positive trend
with dose in this study. It is a fact that the Lenziaren®
treated cats consumed higher quantities of phosphate
as a result of higher food consumption, but the urine
phosphate results suggest that absorption of phosphate
was effectively decreased by Lenziaren®. Significant re-
ductions in serum phosphate concentrations by Lenziaren®,
as one would expect for a phosphate binder, were reported
in previous studies in healthy cats fed a renal diet for
28 days [15] and in cats with CKD [17]. The higher serum
creatinine concentrations in this study might be related to
the maintenance of body weight with Lenziaren® compared
to the control group, but we have no explanation for the
dose-related lower ALP and ALT activities with Lenziaren®.
Similar effects of Lenziaren® on ALP, ALT and creatinine
were not observed in a previous study [15].
Although mean serum iron concentrations in the
Lenziaren® groups (range 16.0-22.0 μmol/L) remained
within the reference range of cats at the study site, con-
centrations were significantly higher in the Lenziaren®
groups compared to the control group, and increased in
a dose-dependent manner. This result is logical since
Lenziaren® is a complex of iron with starch and sucrose,
designed to increase the binding potency to phosphate
and to limit systemic absorption of iron. Nevertheless
small amounts of iron can be absorbed. There were slight
increases from baseline in mean iron concentrations
(+2.0 to +5.1 μmol/L) in the cats receiving Lenziaren®,
whereas both the control (−1.0 μmol/L) and renal diet
(−3.8 μmol/L) groups showed decreases in iron concen-
trations. One explanation for these findings is that the
blood sampling schedule, although it represented only
a total of 63–72 mL of blood over a 9 week period,
may have led to decreases in iron concentrations in
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prevented by the administration of Lenziaren®. Dose-
related increases in plasma iron concentrations were
observed also in cats with hyperphosphataemia and CKD
dosed with 0.125-1.5 g/day Lenziaren® and fed with renal
or standard diet [17 and Novartis data on file]. The mag-
nitude of change from baseline in iron concentrations
was similar in the CKD cats (+3.7 μmol/L) as in this
study (+2.0 to +5.1 μmol/L). Therefore the release of iron
from the Lenziaren® complex and absorption from the
gastrointestinal tract was approximately similar in cats
with CKD and in healthy animals. In contrast, absorption
of iron from the iron-based phosphate binder PA21 was
higher in healthy human subjects compared to patients
undergoing dialysis [19]. That result was attributed to the
effect that oral absorption of iron is reduced by the pres-
ence of uraemia (in humans). No changes in plasma iron
concentrations were observed in humans with hyper-
phosphataemia undergoing dialysis receiving SBR759 at
3.75-22.5 g/day with treatment for 4 weeks [13] or at a
mean dose of 6.2 g/day for 12 weeks [14].
Higher plasma iron concentrations might be relevant
clinically in cats with CKD. Although excessively high
plasma iron concentrations are associated with toxicity
[20], moderately increased iron concentrations are un-
likely to be detrimental since anaemia occurs commonly
in cats with CKD and is a risk factor for mortality [5].
Field studies are required to examine further this topic.
No adverse effects of absorption of iron with Lenziaren®
were detected in this or previous studies in cats [15,17].
A secondary objective of the study was to compare the
efficacy and tolerability of a renal diet with the other
groups (standard diet with and without Lenziaren®). As
compared to the control group (standard diet without
Lenziaren®), the renal diet was associated with significant
loss of body weight (0.42 kg, 12.4%) during the 60 day
study. The feed consumption was 7.3% lower with the
renal diet compared to the standard diet, but differences
were not statistically significant. Poor compliance of cats
to renal diets due to low palatability has been described
previously [2,10]. Cats fed with the renal diet had signifi-
cantly lower urine phosphate concentrations and total
amount of phosphorus excreted in the urine, in addition
to lower faecal and total excretion of phosphorus,
compared with the standard diet. These results can be
explained by the effect of the renal diet in reducing total
intake of phosphorus. The fractional urinary phosphate
excretion was not changed significantly by the renal diet,
as expected, indicating that faecal and urinary phos-
phorus excretions were reduced equally. The amount of
phosphorus consumed by the cats receiving the renal
diet was 53.6% of the standard diet. This can be accounted
for mainly by the lower phosphorus content (60%) of the
renal diet with a smaller contribution from the lower foodconsumption (93%). In a previous study in the same la-
boratory, growing cats fed the same renal diet for approxi-
mately two months showed a small (+0.23 kg) gain in
body weight [15] compared to the loss noted in this study.
One possible reason for this discrepancy is that the cats in
the previous study received a placebo to SBR759 contain-
ing caramel to provide a similar colour to Lenziaren® [15].
As noted in the conclusions of that study, it is possible
that the caramel increased the acceptability of the renal
diet [15]. In spite of the loss of body weight of the cats
receiving the renal diet in this study, the cats were
judged to be in good health in the clinical examinations
and consumed their feed faster than the control group.
No significant changes in haematology or serum chem-
istry variables were observed that could be attributed to
the renal diet.
The main limitations of the study are discussed below.
First, complete blinding of the study was not possible
since two different diets were tested and no suitable pla-
cebo was available for the control group. In a previous
study in cats, a placebo was used with a similar starch
and sucrose complex as SBR759 (without iron) plus
caramel to give a similar colour to Lenziaren®. This pla-
cebo was no longer available for this study. In addition
the placebo was of only limited value as, although its
physical appearance was similar, it did not result in dark-
ening of the faeces as occurs with Lenziaren® as a conse-
quence of its iron content. Since complete blinding was
not possible, the study was masked by separation of func-
tions so that personnel responsible for clinical examina-
tions did not know the treatment groups. In addition,
personnel making the laboratory analyses, which were the
most important endpoints, were blinded to the treatment
groups.
Second, blood samples from the cats were collected
after sedation with xylazine and atipamezole, which
might have affected blood variables, appetite or gastro-
intestinal motility. However any effects should have been
the same in all groups.
Third, the choice of baseline in the statistical analyses
including group F (renal diet) was challenging due to the
unexpected loss of body weight in the renal diet group,
which was most pronounced in the acclimatization
period. The plan for the study was to acclimatize all cats
to their diets prior to day 0. In a previous study in the
same laboratory, a 28 day acclimatization period to the
renal diet was sufficient and the cats had no signifi-
cant changes in feed consumption or body weight dur-
ing the acclimatization period [15]. The unexpected
loss of body weight in the renal diet group in the
acclimatization period resulted in the baseline values
between days −28 and day −1 being unreliable for the
renal diet group (F). For two important variables, body
weight and serum phosphate concentration, baseline values
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with RMANCOVA including baseline. For all other vari-
ables, no baseline was included in the RMANOVA model.
In view of these limitations, the results from the renal diet
group should be treated as exploratory only and additional
studies are recommended. The primary objective of the
study was unaffected by this issue, and the Lenziaren®
and control group were compared for all variables using
RMANCOVA using the baseline values recorded on
day −14 or −30. This was valid since the management of
those cats was the same prior to day 0.
Fourth, parametric methods (ANCOVA or RMAN
COVA) were used since these are more powerful than
non-parametric methods especially for repeated mea-
sures designs as used in this study. The data were log
transformed in many cases, but nevertheless in 50% of
analyses the data in the models deviated significantly
from a normal distribution. However it was judged that
the distributions were satisfactory, and it has been shown
that ANOVA models are relatively robust even when the
distribution deviates from normality [21]. Therefore we
conclude that the statistical analyses were appropriate for
the conclusions reached.
Fifth, the results obtained with the diets tested (Hill’s
Science Plan Adult 1–6 Optimal Care Chicken for the
standard diet, Hill’s Prescription Diet k/d Feline Renal
Heath with Chicken for the renal diet) may not neces-
sarily be extrapolated to other diets.
Lastly, the study was conducted in healthy cats and
therefore the results cannot be simply extrapolated to
clinical cases of hyperphosphataemia in cats. However
efficacy of SBR759 over the dose range 0.25-1.0 g/day
was reported in an abstract of a field study in cats with
hyperphosphataemia secondary to CKD [17].
Conclusions
In healthy cats fed a standard diet, Lenziaren® at doses
of 0.25-2.0 g/cat per day effectively bound oral phos-
phate as evidenced by a dose-related reduction in urine
phosphate concentrations. Lenziaren® was well tolerated
and resulted in higher food consumption and dose-related
increases in serum iron concentrations compared to the
control group.
As compared to the negative control, the renal diet
was associated with lower urine phosphate concentra-
tions but also a loss of body weight. Lenziaren® had simi-
lar effects on serum and urine phosphate concentrations
compared to the renal diet, and was not associated with
loss of body weight.
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